Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by Parametrica Management Ltd

Parametrica Management Ltd boosted its position in Novavax, Inc. (NASDAQ:NVAXGet Rating) by 428.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,539 shares of the biopharmaceutical company’s stock after purchasing an additional 7,733 shares during the quarter. Parametrica Management Ltd’s holdings in Novavax were worth $703,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Qube Research & Technologies Ltd purchased a new position in Novavax during the first quarter valued at approximately $9,839,000. IFM Investors Pty Ltd grew its holdings in shares of Novavax by 19.6% in the 1st quarter. IFM Investors Pty Ltd now owns 11,096 shares of the biopharmaceutical company’s stock worth $817,000 after purchasing an additional 1,819 shares during the last quarter. Banque Cantonale Vaudoise grew its holdings in shares of Novavax by 3,018.2% in the 1st quarter. Banque Cantonale Vaudoise now owns 11,631 shares of the biopharmaceutical company’s stock worth $857,000 after purchasing an additional 11,258 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Novavax by 2.2% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 178,351 shares of the biopharmaceutical company’s stock worth $13,136,000 after purchasing an additional 3,814 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Novavax by 15.7% in the 1st quarter. Swiss National Bank now owns 311,100 shares of the biopharmaceutical company’s stock worth $22,913,000 after purchasing an additional 42,100 shares during the last quarter. 43.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. B. Riley cut their target price on shares of Novavax from $181.00 to $171.00 in a research report on Friday, July 22nd. Cowen decreased their price target on shares of Novavax from $150.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 9th. Cantor Fitzgerald raised their price target on shares of Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th. Bank of America assumed coverage on shares of Novavax in a research note on Friday, May 20th. They set an “underperform” rating and a $35.00 price target for the company. Finally, Cowen decreased their price target on shares of Novavax from $150.00 to $110.00 in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $151.00.

Novavax Price Performance

NVAX opened at $42.72 on Monday. Novavax, Inc. has a fifty-two week low of $34.88 and a fifty-two week high of $277.80. The stock has a fifty day moving average of $52.87 and a 200-day moving average of $62.62.

Novavax (NASDAQ:NVAXGet Rating) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($6.53) EPS for the quarter, missing analysts’ consensus estimates of $5.51 by ($12.04). Novavax had a negative return on equity of 572.54% and a negative net margin of 114.32%. The company had revenue of $186.00 million during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the business posted ($4.75) EPS. The firm’s revenue for the quarter was down 37.6% on a year-over-year basis. On average, equities research analysts predict that Novavax, Inc. will post 20.98 earnings per share for the current fiscal year.

About Novavax

(Get Rating)

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Further Reading

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.